MCID: HYP076
MIFTS: 55

Hyperthyroidism

Categories: Endocrine diseases, Rare diseases

Aliases & Classifications for Hyperthyroidism

MalaCards integrated aliases for Hyperthyroidism:

Name: Hyperthyroidism 12 74 36 29 54 6 42 15 17 71
Overactive Thyroid 12 62

Classifications:



External Ids:

Disease Ontology 12 DOID:7998
KEGG 36 H01645
NCIt 49 C3123
SNOMED-CT 67 34486009
ICD10 32 E05.9
UMLS 71 C0020550

Summaries for Hyperthyroidism

MedlinePlus : 42 What is hyperthyroidism? Hyperthyroidism, or overactive thyroid, happens when your thyroid gland makes more thyroid hormones than your body needs. Your thyroid is a small, butterfly-shaped gland in the front of your neck. It makes hormones that control the way the body uses energy. These hormones affect nearly every organ in your body and control many of your body's most important functions. For example, they affect your breathing, heart rate, weight, digestion, and moods. If not treated, hyperthyroidism can cause serious problems with your heart, bones, muscles, menstrual cycle, and fertility. But there are treatments that can help. What causes hyperthyroidism? Hyperthyroidism has several causes. They include Grave's disease, an autoimmune disorder in which your immune system attacks your thyroid and causes it to make too much hormone. This is the most common cause. Thyroid nodules, which are growths on your thyroid. They are usually benign (not cancer). But they may become overactive and make too much thyroid hormone. Thyroid nodules are more common in older adults. Thyroiditis, inflammation of the thyroid. It causes stored thyroid hormone to leak out of your thyroid gland. Too much iodine. Iodine is found in some medicines, cough syrups, seaweed and seaweed-based supplements. Taking too much of them can cause your thyroid to make too much thyroid hormone. Too much thyroid medicine. This can happen if people who take thyroid hormone medicine for hypothyroidism (underactive thyroid) take too much of it. Who is at risk for hyperthyroidism? You are at higher risk for hyperthyroidism if you Are a woman Are older than age 60 Have been pregnant or had a baby within the past 6 months Have had thyroid surgery or a thyroid problem, such as goiter Have a family history of thyroid disease Have pernicious anemia, in which the body cannot make enough healthy red blood cells because it does not have enough vitamin B12 Have type 1 diabetes or primary adrenal insufficiency, a hormonal disorder Get too much iodine, from eating large amounts of foods containing iodine or using iodine-containing medicines or supplements What are the symptoms of hyperthyroidism? The symptoms of hyperthyroidism can vary from person to person and may include Nervousness or irritability Fatigue Muscle weakness Trouble tolerating heat Trouble sleeping Tremor, usually in your hands Rapid and irregular heartbeat Frequent bowel movements or diarrhea Weight loss Mood swings Goiter, an enlarged thyroid that may cause your neck to look swollen. Sometimes it can cause trouble with breathing or swallowing. Adults over age 60 may have different symptoms than younger adults. For example, they may lose their appetite or withdraw from other people. Sometimes this can be mistaken for depression or dementia. What other problems can hyperthyroidism cause? If hyperthyroidism isn't treated, it can cause some serious health problems, including An irregular heartbeat that can lead to blood clots, stroke, heart failure, and other heart problems An eye disease called Graves' ophthalmopathy. It can cause double vision, light sensitivity, and eye pain. In rare cases, it can lead to vision loss. Thinning bones and osteoporosis Fertility problems in women Complications in pregnancy, such as premature birth, low birth weight, high blood pressure in pregnancy, and miscarriage How is hyperthyroidism diagnosed? To make a diagnosis, your health care provider Will take your medical history, including asking about symptoms Will do a physical exam May do thyroid tests, such as TSH, T3, T4, and thyroid antibody blood tests Imaging tests, such as a thyroid scan, ultrasound, or radioactive iodine uptake test. A radioactive iodine uptake test measures how much radioactive iodine your thyroid takes up from your blood after you swallow a small amount of it. What are the treatments for hyperthyroidism? The treatments for hyperthyroidism include medicines, radioiodine therapy, and thyroid surgery: Medicines for hyperthyroidism include Antithyroid medicines, which cause your thyroid to make less thyroid hormone. You probably need to take the medicines for 1 to 2 years. In some cases, you might need to take the medicines for several years. This is the simplest treatment, but it is often not a permanent cure. Beta blocker medicines, which can reduce symptoms such as tremors, rapid heartbeat, and nervousness. They work quickly and can help you feel better until other treatments take effect. Radioiodine therapy is a common and effective treatment for hyperthyroidism. It involves taking radioactive iodine by mouth as a capsule or liquid. This slowly destroys the cells of the thyroid gland that produce thyroid hormone. It does not affect other body tissues. Almost everyone who has radioactive iodine treatment later develops hypothyroidism. This is because the thyroid hormone-producing cells have been destroyed. But hypothyroidism is easier to treat and causes fewer long-term health problems than hyperthyroidism. Surgery to remove part or most of the thyroid gland is done in rare cases. It might be an option for people with large goiters or pregnant women who cannot take antithyroid medicines. If you have all of your thyroid removed, you will need to take thyroid medicines for the rest of your life. Some people who have part of their thyroid removed also need to take medicines. If you have hyperthyroidism, it's important not to get too much iodine. Talk to your health care provider about which foods, supplements, and medicines you need to avoid. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Hyperthyroidism, also known as overactive thyroid, is related to graves' disease and thyroid hormone resistance, selective pituitary. An important gene associated with Hyperthyroidism is TSHR (Thyroid Stimulating Hormone Receptor), and among its related pathways/superpathways are Peptide ligand-binding receptors and Allograft rejection. The drugs Propylthiouracil and tannic acid have been mentioned in the context of this disorder. Affiliated tissues include thyroid, heart and bone, and related phenotypes are Decreased HPV16-GFP infection and behavior/neurological

Disease Ontology : 12 A thyroid gland disease that involves an over production of thyroid hormone.

KEGG : 36 Hyperthyroidism is a pathological disorder characterised by increased thyroid hormone synthesis and secretion from the thyroid gland. The term thyrotoxicosis is not synonymous with hyperthyroidism. Thyrotoxicosis is defined as the clinical syndrome of hypermetabolism resulting from increased thyroid hormone levels, irrespective of the source. The causes of hyperthyroidism include Graves' disease, toxic multinodular goiter, and solitary toxic adenoma. Less common causes of hyperthyroidism include thyrotropin-induced thyrotoxicosis and trophoblastic tumours. The causes of thyrotoxicosis without hyperthyroidism are less common and generally transient. In patients with silent thyroiditis, post-partum thyroiditis, or subacute painful thyroiditis, the destruction of thyrocytes leads to release of preformed hormones into the circulation. Drug-induced thyrotoxicosis has the same pathogenic mechanism as thyroiditis. Exogenous thyrotoxicosis develops after ingestion of excessive amounts of thyroid hormone, and is associated with low serum thyroglobulin concentrations. Patients of hyperthyroidism/thyrotoxicosis usually have fatigue, nervousness or anxiety, weight loss, palpitations, and heat sensitivity. Clinical findings almost always include tachycardia, warm moist skin, the presence of an enlarged thyroid, and a slight tremor. The three options for treating patients with hyperthyroidism are antithyroid drugs (ATDs), radioactive iodine ablation, and surgery. All three therapeutic options would be effective in the treatment of patients with Graves' disease, whereas patients with toxic adenoma or toxic multinodular goiter should have either radioactive iodine therapy or surgery, since these patients rarely go into remission. In patients with toxic nodular goiter, ATDs are generally used to restore euthyroidism before definitive treatment with surgery or radioactive iodine, and infrequently used as long-term treatment when the other two therapies are contraindicated or the patient has a short life expectancy.

PubMed Health : 62 About overactive thyroid: The thyroid gland is a part of the body’s endocrine (hormone) system – which is made up of the glands that help regulate many of the body’s different functions. If the thyroid gland is overactive, it produces too much of the thyroid hormone thyroxine. An overactive thyroid (medical term: hyperthyroidism) can be caused by various things. The most common cause is a condition known as Graves disease. The higher levels of thyroid hormones unnecessarily speed up a lot of functions in the body. This can lead to noticeable symptoms such as weight loss, sweating, nervousness or a rapid heartbeat. An overactive thyroid increases the risk of cardiovascular disease (problems affecting the heart and/or blood vessels). If the thyroid gland doesn’t produce enough hormones, the body’s functions slow down. This problem is known as an underactive thyroid or hypothyroidism.

Wikipedia : 74 Hyperthyroidism is the condition that occurs due to excessive production of thyroid hormones by the... more...

Related Diseases for Hyperthyroidism

Diseases in the Hyperthyroidism family:

Rare Hyperthyroidism

Diseases related to Hyperthyroidism via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 989)
# Related Disease Score Top Affiliating Genes
1 graves' disease 34.1 TSHR TPO THRB TG SERPINA7 GNAS
2 thyroid hormone resistance, selective pituitary 33.9 TRH THRB SST
3 graves disease 1 33.2 TSHR TRH TPO THRB TG SHBG
4 myxedema 33.1 TSHR TPO TG SERPINA7 CTLA4
5 thyroid crisis 33.1 TSHR TPO THRB TG SERPINA7
6 hypoparathyroidism 32.8 TPO GNAS CTLA4 BGLAP ALPP
7 pituitary tumors 32.5 SST PRL GNAS GH1
8 struma ovarii 32.3 TSHR TG
9 mccune-albright syndrome 32.2 SST PRL LEP GNAS GH1 BGLAP
10 plummer's disease 32.2 TSHR TPO THRB TG SHBG
11 neonatal thyrotoxicosis 32.1 TSHR TG
12 thyroid carcinoma 32.0 TSHR TPO TG
13 multinodular goiter 31.8 TSHR TPO TG GNAS
14 nodular goiter 31.8 TSHR TPO TG CTLA4
15 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 31.5 TSHR TPO TG CTLA4
16 hashimoto thyroiditis 31.2 TSHR TPO TG GHRL CTLA4
17 thyroiditis 31.2 TSHR TRH TPO THRB TG SERPINA7
18 papillary carcinoma 31.2 TSHR TPO TG GNAS
19 exophthalmos 31.2 TSHR TPO TG PRTN3 PRL
20 autoimmune disease 31.1 TSHR TPO TG PRTN3 CTLA4
21 thyroid cancer, nonmedullary, 2 31.1 TSHR THRB TG
22 endemic goiter 31.1 TSHR TPO TG SERPINA7
23 subacute thyroiditis 31.1 TSHR TPO TG SHBG SERPINA7 SERPINA6
24 parathyroid adenoma 31.0 GNAS BGLAP ALPP
25 goiter 31.0 TSHR TRH TPO THRB TG SST
26 differentiated thyroid carcinoma 31.0 TSHR TPO TG BGLAP
27 primary hyperparathyroidism 31.0 PRL BGLAP ALPP
28 hypothyroidism 31.0 TSHR TRH TPO THRB TG SST
29 adenoma 31.0 TSHR TRH TG SST PRL GNAS
30 postsurgical hypothyroidism 30.8 TRH TPO TG
31 thyroid tumor 30.8 TPO THRB TG
32 toxic diffuse goiter 30.8 TSHR TPO TG SERPINA7
33 gynecomastia 30.8 SHBG PRL LEP CGA
34 hyperthyroxinemia 30.8 TSHR TRH TPO THRB TG SERPINA7
35 glucose intolerance 30.7 SHBG LEP GHRL GH1
36 pernicious anemia 30.6 TPO TG SST
37 orbital disease 30.6 TSHR TG PRTN3
38 hypoglycemia 30.5 SST PRL GHRL GH1
39 pituitary adenoma 30.5 TRH SST PRL GNAS GHRL GH1
40 thyroid gland follicular carcinoma 30.5 TSHR TPO THRB TG
41 chromophobe adenoma 30.5 TRH PRL GH1
42 hypothyroidism, congenital, nongoitrous, 1 30.5 TSHR TG GNAS
43 follicular adenoma 30.5 TSHR TPO TG GNAS
44 nontoxic goiter 30.5 TSHR TPO TG SHBG SERPINA7 BGLAP
45 thyroid lymphoma 30.5 TPO TG
46 anca-associated vasculitis 30.4 PRTN3 GHRL CTLA4
47 congenital hypothyroidism 30.4 TSHR TPO TG SHBG SERPINA7 PRL
48 hyperinsulinism 30.4 SST SHBG LEP GHRL GH1
49 fibrous dysplasia 30.4 SST PRL GNAS GH1 BGLAP
50 hyperglycemia 30.3 SST LEP GHRL GH1

Graphical network of the top 20 diseases related to Hyperthyroidism:



Diseases related to Hyperthyroidism

Symptoms & Phenotypes for Hyperthyroidism

GenomeRNAi Phenotypes related to Hyperthyroidism according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased HPV16-GFP infection GR00350-A 8.62 GNAS TRH

MGI Mouse Phenotypes related to Hyperthyroidism:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.11 GHRL GNAS LEP PRL SERPINA6 SST
2 endocrine/exocrine gland MP:0005379 10.03 BGLAP CGA CTLA4 GHRL GNAS LEP
3 homeostasis/metabolism MP:0005376 10.03 BGLAP CGA CTLA4 GHRL GNAS LEP
4 digestive/alimentary MP:0005381 9.87 CTLA4 GHRL LEP SST TG THRB
5 immune system MP:0005387 9.73 BGLAP CTLA4 GNAS LEP PRL PRTN3
6 skeleton MP:0005390 9.36 BGLAP CTLA4 GNAS LEP SDHA SST

Drugs & Therapeutics for Hyperthyroidism

PubMed Health treatment related to Hyperthyroidism: 62

Mild hyperthyroidism sometimes gets better on its own, without treatment . But the overproduction of thyroid hormones is usually first stopped using tablets called anti-thyroid drugs. In Graves disease , long-term treatment with this medication can make the thyroid function return to normal. If that doesn’t happen, the thyroid gland is surgically removed or treated with radioactive iodine . Known as radioiodine therapy , this involves swallowing radioactive iodine which is then absorbed by your thyroid gland, where it destroys overactive cells . If the overactive thyroid is caused by an enlarged thyroid gland with “autonomous” cells , the thyroid gland that has been “slowed down” with anti-thyroid drugs is usually surgically removed. If surgery isn’t possible or the thyroid gland isn’t greatly enlarged, radioiodine therapy tends to be more suitable.

Drugs for Hyperthyroidism (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 229)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Propylthiouracil Approved, Investigational Phase 4 51-52-5 657298
2
tannic acid Approved Phase 4 1401-55-4
3
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
4
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
5
Tocopherol Approved, Investigational Phase 4 1406-66-2, 54-28-4 14986
6
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
7
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
8
Propranolol Approved, Investigational Phase 4 525-66-6 4946
9
Methimazole Approved Phase 4 60-56-0 1349907
10
Cinacalcet Approved Phase 4 226256-56-0 156419
11
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
12
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
13
Histamine Approved, Investigational Phase 4 51-45-6 774
14
Clonidine Approved Phase 4 4205-90-7 2803
15
Mirtazapine Approved Phase 4 85650-52-8, 61337-67-5 4205
16
Acetaminophen Approved Phase 4 103-90-2 1983
17
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
18
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
19
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
20
rituximab Approved Phase 4 174722-31-7 10201696
21
Methotrexate Approved Phase 4 59-05-2, 1959-05-2 126941
22
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
23
Racepinephrine Approved Phase 4 329-65-7 838
24
Febuxostat Approved Phase 4 144060-53-7 134018
25
Amiodarone Approved, Investigational Phase 4 1951-25-3 2157
26
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
27
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
28
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938
29
Alfacalcidol Approved, Nutraceutical Phase 4 41294-56-8 5282181
30
Calcitriol Approved, Nutraceutical Phase 4 32222-06-3 5280453 134070
31 Tocotrienol Investigational Phase 4 6829-55-6
32
Uric acid Investigational Phase 4 69-93-2 1175
33 Trace Elements Phase 4
34 Nutrients Phase 4
35 Micronutrients Phase 4
36 Lipid Regulating Agents Phase 4
37 Hypolipidemic Agents Phase 4
38 Antimetabolites Phase 4
39 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
40 Vitamin B Complex Phase 4
41 Folate Phase 4
42 Vitamin B9 Phase 4
43 Dopamine Agents Phase 4
44 Dopamine agonists Phase 4
45 Tocotrienols Phase 4
46 Tocopherols Phase 4
47 Dopamine Antagonists Phase 4
48 Serotonin Receptor Agonists Phase 4
49 Serotonin 5-HT1 Receptor Agonists Phase 4
50 Antipsychotic Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 204)
# Name Status NCT ID Phase Drugs
1 The Effect of Early Total Thyroidectomy in the Course of Graves' Orbitopathy Unknown status NCT01056419 Phase 4 Propylthiouracil
2 Total Thyroidectomy With Harmonic Scalpel® Versus Standard Surgery. Open Multicentric Randomized Controlled Trial Unknown status NCT00385983 Phase 4
3 Assessment of Intellectual, Psychological and Behavioural Developments Between 6 and 9 Years of the Children Born to Hyperthyroid Mothers During Pregnancy Unknown status NCT01779817 Phase 4
4 Cardiopulmonary Capacity In Different Quartiles Ranges Of Reference For Serum Thyroid Stimulating Hormone (TSH): Sectional Evaluation And Effect Of The Use Of Methimazole In Elderly Population Unknown status NCT01849861 Phase 4 Methimazole
5 Maintenance of Vitamin D Sufficiency With Oral Vitamin D Supplementation in Malaysian Women of Malay and Indian Ethnicity With Post Menopausal Osteoporosis Unknown status NCT02389179 Phase 4 Vitamin D3
6 The Monitor of Serum Prolactin Level and Related Clinical Observations Among Individuals With Schizophrenia Spectrum Illnesses in a 3 Months Aripiprazole Trial Unknown status NCT00468533 Phase 4 Aripiprazole
7 The Low HDL On Six Weeks Statin Therapy (LOW) Study Unknown status NCT00238004 Phase 4 Nicotinic acid
8 Short Term Effects of Propanolol on Heart Rate Variability of Hyperthyroidism Completed NCT03393728 Phase 4 Propanolol
9 Thermogenesis in Hyperthyroidism and Effect of Anti-Adrenergic Therapy Completed NCT03379181 Phase 4 Propranolol
10 A Multicenter, Randomized, Open Label Study to Compare the Efficacy of Cinacalcet Versus Traditional Vitamin D Therapy for Management of Secondary Hyperparathyroidism Among Subjects Undergoing Hemodialysis Completed NCT01181531 Phase 4 Traditional Vitamin D Therapy;Cinacalcet
11 Impact of SSKI Pre-Treatment on Blood Loss in Thyroidectomy for Graves Disease Completed NCT00946296 Phase 4 Potassium Iodide
12 The Influence of Continuous Treatment With Antithyroid Drugs on the Effect of Radioiodine in Patients With Hyperthyroidism Completed NCT00150137 Phase 4 Methimazole
13 The Influence of Continuous Block-replacement Therapy on the Effect of Radioiodine in Patients With Hyperthyroidism Completed NCT00150124 Phase 4 MTZ+LT4;Methimazole
14 Prevention Relapse of Graves' Disease by Treatment With Intrathyroid Injection of Dexamethasone Completed NCT00917241 Phase 4 MMI combined with IID;MMI
15 Prophylactic Mirtazapine or Clonidine for Post-spinal Anesthesia Shivering in Patients Undergoing Urological Surgeries: a Randomized Controlled Trial Completed NCT03679052 Phase 4 Mirtazapine;Clonidine;Placebo
16 Prophylactic Mirtazapine or Dexamethasone for Post-spinal Anesthesia Shivering in Patients Undergoing Gynecological Surgeries: a Randomized Controlled Trial Completed NCT03675555 Phase 4 Mirtazapine;Dexamethasone phosphate;Placebo
17 Prophylactic Paracetamol or Dexamethasone for Post-spinal Anesthesia Shivering in Patients Undergoing Non-obstetric Surgeries: a Randomized Controlled Trial Completed NCT03679065 Phase 4 Paracetamol;Dexamethasone;Placebo
18 EFFICACY OF KETAMINE-PROPOFOL COMBINATION FOR SHORT SURGICAL PROCEDURES Completed NCT01651988 Phase 4 Ketamina-Propofol Combination
19 Effect Of Hormone Replacement Therapy On Disease Activity, Menopausal Symptoms And Bone Mineral Density In Peri/Postmenopausal Women With Systemic Lupus Erythematosus.Randomized Clinical Trial Completed NCT00392093 Phase 4 Conjugated equine estrogens 0.625 mg/d + MPA 5 mg/d/10d
20 A Comparison of Isolating the Pulmonary Veins With the Cryoballoon Catheter Versus Radiofrequency Segmental Isolation:a Randomized Controlled Prospective Non-inferiority Trial Completed NCT00774566 Phase 4
21 Randomized Clinical Trial, Blinded for the Researcher and Multicenter, to Evaluate the Efficacy and Safety of Preoperative Preparation With Lugol Solution in Euthyroid Patients With Graves-Basedow Disease. Recruiting NCT03980132 Phase 4 Lugols Strong Iodine
22 Rituximab (RTX) Therapy in Steroid Resistant Patients or Patients Relapsing After Intravenous Steroids With Active TAO Recruiting NCT02378298 Phase 4 Rituximab;Iv Methylprednisolone;peroral methylprednisolone and Methotrexate
23 Pain Perception Associated With Administration of Buffered Lidocaine Versus Conventional Lidocaine in the Pediatric Dental Patient Recruiting NCT04055116 Phase 4 Buffered Lidocaine
24 Department of Urology, Shanghai Xu-hui Central Hospital Enrolling by invitation NCT04398251 Phase 4 Febuxostat 40mg Tab
25 Discontinuation of Levothyroxine Therapy for Patients With Subclinical Hypothyroidism: a Pilot Randomized, Double-blinded, Placebo-controlled Study Not yet recruiting NCT04288115 Phase 4 Levothyroxine
26 Use of Amiodarone in Atrial Fibrillation Associated With Severe Sepsis or Septic Shock Terminated NCT02668432 Phase 4 Amiodarone
27 Pilot Double-Blind Placebo Controlled Trial of Levothyroxine in Pregnant Systemic Lupus Erythematosus (SLE) Patients With Autoimmune Thyroid Disease Withdrawn NCT01276782 Phase 4 Levothyroxine
28 Therapeutic Role of Levothyroxine on the Patients With Atypia of Undetermined Significance (AUS) Goiter Withdrawn NCT02329379 Phase 4 Levothyroxine
29 A Multi-center, Open Label, Randomised Parallel- Group Study to Compare the Efficacy of Cholestyramine Plus Standard Treatment Versus Prednisolone Plus Standard Treatment Versus Standard Treatment Alone in Treatment of Overt Hyperthyroidism Unknown status NCT03303053 Phase 3 Cholestyramine Powder 4g;Prednisolone;Standard treatment
30 Levothyroxine Treatment of Subclinical Hypothyroidism After Non-thyroid Head and Neck Surgery: A Randomized Controlled Trial Unknown status NCT02548715 Phase 2, Phase 3 Levothyroxine;Placebo
31 Comparison of Different Doses of 131I in Severe Graves' Hyperthyroidism: A Clinical Trial With Historical Control Completed NCT01039818 Phase 3
32 Calcium Nephrolithiasis: Clinical Characteristics and Nutritional Determinants Completed NCT01005082 Phase 2, Phase 3
33 Thyroid Nodules Treated With Percutaneous Radiofrequency Thermal Ablation: a Comparative Study Completed NCT01649206 Phase 3
34 Early Administration of L-carnitine in Hemodialysis Patients: Double Blind Randomized Trial Versus Placebo Completed NCT00322322 Phase 3 L-Carnitine
35 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Hemodynamic and Clinical Effects of Natrecor (Nesiritide) Compared With Nitroglycerin Therapy for Symptomatic Decompensated CHF, The VMAC Trial: Vasodilation in the Management of Acute Congestive Heart Failure Completed NCT00270374 Phase 3 nesiritide
36 Does the Use of Pre-operative SSKI Actually Reduce Vascularity and Improve Surgical Outcomes for Total Thyroidectomy in Graves' Disease? Recruiting NCT04080505 Phase 3 SSKI- Potassium Iodide
37 Treatment of Graves´Ophthalmopathy With Simvastatin (GO-DS) Recruiting NCT03131726 Phase 3 Simvastatin 40mg
38 Investigation of Novel Biomarkers and Definition of the Role of the Microbiome In Graves' Orbitopathy Unknown status NCT02373995 Phase 1, Phase 2
39 The Effect of Subantimicrobial Dose Doxycycline in Mild Graves' Orbitopathy Unknown status NCT02203682 Phase 2 Doxycycline;placebo
40 A Phase I/ II Clinical Trial of MDV9300 (Pidilizumab) in Diffuse Intrinsic Pontine Glioma Unknown status NCT01952769 Phase 1, Phase 2
41 An Open Label Study to Evaluate the Safety and Efficacy of 12 Week Treatment With CFZ533 in Patients With Graves' Disease Completed NCT02713256 Phase 2 CFZ533
42 A Phase II, Placebo-Controlled, Double-Blind, Randomised, 12-Week, Parallel-Group Study to Assess the Efficacy of Different Doses of KB2115 as Add on to Statin Treatment in Patients With Dyslipidemia Completed NCT00593047 Phase 2 KB2115
43 A Placebo Controlled, Double Blind, Randomised, 12-Week, Phase ii Study to Assess the Safety and Efficacy of KB2115 in Patients With Primary Hypercholesterolemia Completed NCT00776321 Phase 2 Eprotirome;Placebo
44 A Phase II, Placebo-Controlled, Double-Blind, Randomised, 10-Week, Parallel-Group Study to Assess the Efficacy of Different Doses of KB2115 as Add on to Ezetimibe Treatment in Patients With Primary Hypercholesterolemia Completed NCT00677248 Phase 2 Ezetimibe and placebo;Eprotirome and ezetimibe
45 Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy: a Prospective, Uncontrolled Pilot Study Completed NCT01727973 Phase 1, Phase 2 Doxycycline
46 Thyroid Hormone to Induce Non-Insulin Mediated Glucose Disposal in Patients With Insulin Receptor Mutations Completed NCT02457897 Phase 2 Liothyronine
47 Thyroid Hormone Analog Therapy of Patients With Severe Psychomotor Retardation Caused by Mutations in the MCT8 Thyroid Hormone Transporter: The Triac Trial. Completed NCT02060474 Phase 2 Triac
48 Pretreatment With Recombinant Human Thyrotropin (rhTSH) for the Effect on Thyroid Size and Function, and for the Effect of Radioiodine Treatment in Patients With Nodular Goiter. Prospective, Randomized Double-blinded Trials. Completed NCT00145366 Phase 2 Recombinant human thyrotropin (Thyrogen)
49 B Cell Depletion With the Anti-CD20 Monoclonal Antibody Rituximab in the Treatment of Graves' Disease Completed NCT00150111 Phase 1, Phase 2 Methimazole;Rituximab
50 The Effects of Thyroid Hormone on Cytochrome P450 and P-Glycoprotein Activity in Thyroid Cancer Patients Completed NCT00080574 Phase 2

Search NIH Clinical Center for Hyperthyroidism

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Sodium Iodide
Sodium iodide I123

Genetic Tests for Hyperthyroidism

Genetic tests related to Hyperthyroidism:

# Genetic test Affiliating Genes
1 Hyperthyroidism 29

Anatomical Context for Hyperthyroidism

MalaCards organs/tissues related to Hyperthyroidism:

40
Thyroid, Heart, Bone, Testes, Pituitary, Liver, Brain

Publications for Hyperthyroidism

Articles related to Hyperthyroidism:

(show top 50) (show all 19881)
# Title Authors PMID Year
1
Evaluation of the C2HEST Risk Score as a Possible Opportunistic Screening Tool for Incident Atrial Fibrillation in a Healthy Population (From a Nationwide Danish Cohort Study). 42 61
31711634 2020
2
Teprotumumab for the Treatment of Active Thyroid Eye Disease. 42
31971679 2020
3
Efficacy and safety of tripterygium glycosides for Graves ophthalmopathy: A systematic review and meta-analysis. 42
31852090 2019
4
Genetic defects, thyroid growth and malfunctions of the TSHR in pediatric patients. 54 61
20515734 2010
5
Genetics and phenomics of inherited and sporadic non-autoimmune hyperthyroidism. 61 54
20138963 2010
6
Immunoglobulin heavy chain variable region genes contribute to the induction of thyroid-stimulating antibodies in recombinant inbred mice. 54 61
20407472 2010
7
Lack of consistent association of thyrotropin receptor mutations in vitro activity with the clinical course of patients with sporadic non-autoimmune hyperthyroidism. 54 61
19636218 2010
8
Hyperthyroidism caused by a germline activating mutation of the thyrotropin receptor gene: difficulties in diagnosis and therapy. 54 61
20146656 2010
9
Pathogenesis of thyroid eye disease--does autoimmunity against the TSH receptor explain all cases? 61 54
20464711 2010
10
Thyrotropin receptor autoantibody measurement following radiometabolic treatment of hyperthyroidism: comparison between different methods. 61 54
20418655 2010
11
Recommendations for investigation of hyperandrogenism. 61 54
20096825 2010
12
A clinical retrospective analysis of factors associated with apathetic hyperthyroidism. 61 54
20185967 2010
13
Prevalence of paraneoplastic hyperthyroidism in patients with metastatic non-seminomatous germ-cell tumors. 61 54
19605510 2010
14
I-131 treatment of graves' disease in an unsuspected first trimester pregnancy; the potential for adverse effects on the fetus and a review of the current guidelines for pregnancy screening. 54 61
20300595 2010
15
Diagnosis and discrimination of autoimmune Graves' disease and Hashimoto's disease using thyroid-stimulating hormone receptor-containing recombinant proteoliposomes. 54 61
19914592 2009
16
More hypothyroidism and less hyperthyroidism with sufficient iodine nutrition compared to mild iodine deficiency--a comparative population-based study of older people. 61 54
19762181 2009
17
Graves hyperthyroidism after stopping immunosuppressive therapy in type 1 diabetic Islet cell recipients with pretransplant TPO autoantibodies. 54 61
19549735 2009
18
Current insights into the pathogenesis of Graves' orbitopathy. 61 54
19530272 2009
19
[31-year-old male patient with testicular mass and hyperthyroidism]. 61 54
19219417 2009
20
The use of plasmapheresis for rapid hormonal control in severe hyperthyroidism caused by a partial molar pregnancy. 54 61
18726107 2009
21
[Thyroid-stimulating hormone receptor antibodies in the diagnosis of Graves' disease in children]. 54 61
19388481 2009
22
Evidence that shed thyrotropin receptor A subunits drive affinity maturation of autoantibodies causing Graves' disease. 54 61
19066298 2009
23
A somatic gain-of-function mutation in the thyrotropin receptor gene producing a toxic adenoma in an infant. 54 61
19191749 2009
24
Ghrelin response to oral glucose load in hyperthyroidism, before and after treatment with antithyroid drugs. 61 54
19411802 2009
25
[Analysis of serum levels of ghrelin and obestatin in children and adolescents with autoimmune thyroid diseases]. 54 61
19454185 2009
26
[Thyroid disorders during pregnancy]. 61 54
19142837 2009
27
First automated assay for thyrotropin receptor autoantibodies. 54 61
19634982 2009
28
Pituitary-hormone secretion by thyrotropinomas. 61 54
19051037 2009
29
Implications of new monoclonal antibodies and the crystal structure of the TSH receptor for the treatment and management of thyroid diseases. 61 54
20477447 2008
30
A low-molecular-weight antagonist for the human thyrotropin receptor with therapeutic potential for hyperthyroidism. 61 54
18669595 2008
31
A family with a novel TSH receptor activating germline mutation (p.Ala485Val). 54 61
18175146 2008
32
Evaluation of a new rapid and fully automated electrochemiluminescence immunoassay for thyrotropin receptor autoantibodies. 54 61
19014323 2008
33
Serum concentrations of adiponectin and resistin in hyperthyroid Graves' disease patients. 54 61
18997483 2008
34
Peripheral blood T lymphocyte sensitisation against calsequestrin and flavoprotein in patients with Graves' ophthalmopathy. 54 61
18568642 2008
35
Serum ghrelin levels are increased in hypothyroid patients and become normalized by L-thyroxine treatment. 61 54
18381578 2008
36
Multiple relapses of hyperthyroidism after thyroid surgeries in a patient with long term follow-up of sporadic non-autoimmune hyperthyroidism. 61 54
18528812 2008
37
A new silent germline mutation of the TSH receptor: coexpression in a hyperthyroid family member with a second activating somatic mutation. 54 61
18466076 2008
38
Serum leptin and ghrelin levels in premenopausal women with stable body mass index during treatment of thyroid dysfunction. 54 61
18466078 2008
39
Thyroid storm caused by a partial hydatidiform mole. 61 54
18352822 2008
40
Selenium analogues of antithyroid drugs--recent developments. 61 54
18357551 2008
41
A novel TSHR gene mutation (Ile691Phe) in a Chinese family causing autosomal dominant non-autoimmune hyperthyroidism. 54 61
18306976 2008
42
A novel thyrotropin receptor germline mutation (Asp617Tyr) causing hereditary hyperthyroidism. 54 61
18025759 2007
43
The link between Graves' disease and Hashimoto's thyroiditis: a role for regulatory T cells. 54 61
17823263 2007
44
Eye signs and serum eye muscle and collagen XIII antibodies in patients with transient and progressive thyroiditis. 54 61
17887926 2007
45
Pediatric thyroid testing issues. 61 54
18167471 2007
46
Negative feedback regulation of hypophysiotropic thyrotropin-releasing hormone (TRH) synthesizing neurons: role of neuronal afferents and type 2 deiodinase. 61 54
17588648 2007
47
Low TSH levels are not associated with osteoporosis in childhood. 61 54
17656602 2007
48
A new case of familial nonautoimmune hyperthyroidism caused by the M463V mutation in the TSH receptor with anticipation of the disease across generations: a possible role of iodine supplementation. 54 61
17696839 2007
49
Sources of circulating 3,5,3'-triiodothyronine in hyperthyroidism estimated after blocking of type 1 and type 2 iodothyronine deiodinases. 61 54
17389703 2007
50
Human chorionic gonadotropin-induced hyperthyroidism in germ cell cancer--a case presentation and review of the literature. 54 61
17585415 2007

Variations for Hyperthyroidism

ClinVar genetic disease variations for Hyperthyroidism:

6 ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 46;X;t(X;3)(p21.3;p25.1)dnTranslocation Pathogenic 268009

Expression for Hyperthyroidism

Search GEO for disease gene expression data for Hyperthyroidism.

Pathways for Hyperthyroidism

Pathways related to Hyperthyroidism according to GeneCards Suite gene sharing:

(show all 14)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.94 TSHR TRH THRB SST PRL LEP
2
Show member pathways
12.63 TSHR TPO TG CTLA4 CGA
3
Show member pathways
12.57 TSHR TPO TG SERPINA7 GNAS CGA
4
Show member pathways
12.29 PRL LEP GH1 CGA
5 11.99 TSHR SST GNAS GHRL CGA
6
Show member pathways
11.97 LEP GHRL GH1 CGA
7 11.68 LEP BGLAP ALPP
8 11.57 PRL CGA BGLAP
9 11.47 TSHR GNAS CGA
10 11.36 TSHR GNAS CGA
11 11.2 THRB CGA BGLAP
12 10.63 PRL LEP GHRL
13 10.62 TSHR CGA
14 9.8 TSHR TRH TPO TG CGA

GO Terms for Hyperthyroidism

Cellular components related to Hyperthyroidism according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.73 TPO TG SST SERPINA7 SERPINA6 PRTN3
2 extracellular region GO:0005576 9.47 TRH TG SST SHBG SERPINA7 SERPINA6
3 endosome lumen GO:0031904 9.16 PRL GH1

Biological processes related to Hyperthyroidism according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.09 TSHR TRH TG PRL LEP GNAS
2 positive regulation of cell proliferation GO:0008284 9.91 TSHR PRTN3 PRL LEP CGA
3 female pregnancy GO:0007565 9.7 PRL LEP GNAS
4 positive regulation of multicellular organism growth GO:0040018 9.58 TSHR GHRL GH1
5 positive regulation of cold-induced thermogenesis GO:0120162 9.56 TSHR LEP GNAS GHRL
6 energy reserve metabolic process GO:0006112 9.55 LEP GNAS
7 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.54 PRL GH1
8 positive regulation of JAK-STAT cascade GO:0046427 9.54 PRL LEP GH1
9 thyroid gland development GO:0030878 9.5 THRB TG CGA
10 positive regulation of growth GO:0045927 9.49 GHRL GH1
11 hormone biosynthetic process GO:0042446 9.48 TPO TG
12 adult feeding behavior GO:0008343 9.46 LEP GHRL
13 thyroid hormone generation GO:0006590 9.33 TPO TG CGA
14 hormone-mediated signaling pathway GO:0009755 9.26 TSHR TRH THRB GHRL
15 response to nutrient levels GO:0031667 9.02 PRL LEP GHRL GH1 BGLAP

Molecular functions related to Hyperthyroidism according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.23 TRH TG SST PRL LEP GHRL
2 prolactin receptor binding GO:0005148 8.96 PRL GH1

Sources for Hyperthyroidism

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....